Analyst Price Target is $5.40
▲ +300.00% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Ocugen in the last 3 months. The average price target is $5.40, with a high forecast of $8.00 and a low forecast of $3.50. The average price target represents a 300.00% upside from the last price of $1.35.
Current Consensus is
The current consensus among 5 polled investment analysts is to buy stock in Ocugen. This Buy consensus rating has held steady for over two years.
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.